Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study.

Rajamand Ekberg N, Bodholdt U, Catarig AM, Catrina SB, Grau K, Holmberg CN, Klanger B, Knudsen ST

Primary care diabetes25 Jun 2021Cited by 55 (Europe PMC)

PMID34183269DOI10.1016/j.pcd.2021.06.008PepBankPUB-34183269

Summary

AimsAs part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden.MethodsSURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion. Primary (change in HbA_1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).ResultsOf the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA_1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA_1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide.ConclusionsIn routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use. CLINICALTRIALS.Gov identifierNCT03648281.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Denmark and Sweden, once-weekly semaglutide lowered HbA1c by an estimated 1.2 percentage points.
In plain wordsIn adults with type 2 diabetes in Denmark and Sweden, once-weekly semaglutide was linked to a lower HbA1c, about 1.2 percentage points.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change from baseline to end of study
Study
n = 282
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
HbA1c change
−1.2 %-points
end of study
Source sentences
Summary
For the latter, estimated mean changes [95% confidence interval] in HbA_1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden.
2 context sentences(design, population, supporting numbers)
Summary · context
Primary (change in HbA_1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Summary · context
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion.
Show in the study text Report a problemFND-3418326901
02HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Denmark and Sweden, once-weekly semaglutide lowered body weight by an estimated 5.4 kg.
In plain wordsIn adults with type 2 diabetes in Denmark and Sweden, once-weekly semaglutide was linked to weight loss of about 5.4 kg.
Peptide
Semaglutide
Outcome
DecreaseBody weight change from baseline to end of study
Study
n = 282
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Body weight change
−5.4 kg
end of study
Source sentences
Summary
For the latter, estimated mean changes [95% confidence interval] in HbA_1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden.
2 context sentences(design, population, supporting numbers)
Summary · context
Primary (change in HbA_1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS).
Summary · context
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion.
Show in the study text Report a problemFND-3418326902
03HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Denmark and Sweden, 67.5% reached HbA1c below 7% at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Denmark and Sweden, 67.5% reached an HbA1c below 7% on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with HbA1c below 7%
Study
n: not reported in source
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion HbA1c <7%
67.5%
end of study
Source sentences
Summary
At EOS, 67.5% of patients achieved HbA_1c <7%
1 context sentence(design, population, supporting numbers)
Summary · context
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion.
Show in the study text Report a problemFND-3418326903
04HumanObservational studyEfficacy outcome
In adults with type 2 diabetes in Denmark and Sweden, 49.4% achieved weight reduction of 5% or more at end of study on once-weekly semaglutide.
In plain wordsIn adults with type 2 diabetes in Denmark and Sweden, 49.4% lost at least 5% of body weight on once-weekly semaglutide.
Peptide
Semaglutide
Outcome
IncreaseProportion with weight reduction of 5% or more
Study
n: not reported in source
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Measurements
Proportion with weight reduction >=5%
49.4%
end of study
Source sentences
Summary
49.4% achieved a weight reduction of ≥5%.
1 context sentence(design, population, supporting numbers)
Summary · context
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion.
Show in the study text Report a problemFND-3418326904
05HumanObservational studySafety outcome
In adults with type 2 diabetes in Denmark and Sweden, reported adverse events with once-weekly semaglutide matched its known safety profile.
In plain wordsIn adults with type 2 diabetes in Denmark and Sweden, reported side effects matched what is already known for semaglutide.
Peptide
Semaglutide
Outcome
Not applicableAdverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · ~30 weeksAs given in this study (human).
Source sentences
Summary
Reported adverse events were consistent with the known safety profile of semaglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA_1c value ≤12 weeks before initiating semaglutide at their physician's discretion.
Show in the study text Report a problemFND-3418326905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT06426446

Monitoring Patients With Severe Obesity Treated With Wegovy® Using Connected Device: Real-world Data

Assistance Publique - Hôpitaux de Parisn = 80est. 1 Jun 2024 to est. 1 Jun 2025

Obesity

Trial page ClinicalTrials.govUpdated 23 May 2024

CompletedPhase not statedNCT03648281

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)

Novo Nordisk A/Sn = 33324 Aug 2018 to 10 Jan 2020

Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 15 Nov 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.